Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Terns Pharmaceuticals Inc TERN

Healthcare Biotechnology
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors... see more

Recent & Breaking News (NDAQ:TERN)

Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

GlobeNewswire October 16, 2023

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire October 3, 2023

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire September 6, 2023

Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

GlobeNewswire September 5, 2023

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

GlobeNewswire August 8, 2023

Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

GlobeNewswire August 8, 2023

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire August 3, 2023

Terns Pharmaceuticals Announces Leadership Transition

GlobeNewswire August 3, 2023

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

GlobeNewswire July 18, 2023

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire July 5, 2023

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA's 83rd Annual Scientific Session and Upcoming Events

GlobeNewswire June 26, 2023

Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

GlobeNewswire June 6, 2023

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire June 2, 2023

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

GlobeNewswire May 25, 2023

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire May 24, 2023

Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association's 83rd Annual Scientific Sessions

GlobeNewswire May 22, 2023

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates

GlobeNewswire May 15, 2023

Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference

GlobeNewswire May 9, 2023

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2023

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

GlobeNewswire March 27, 2023